

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: September 30, 2023

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number 000-56075

4Front Ventures Corp.

(Exact name of registrant as specified in its charter)

British Columbia

83-4168417

(State or other jurisdiction of
incorporation or organization)

(IRS Employer
Identification No.)

7010 E. Chauncey Lane

Suite 235

Phoenix, Arizona 85054

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (602) 633-3067

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Class A Subordinate Voting Shares, no par value	FFNTF	OTCQX
	FFNT	CSE

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes
No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer

Non-accelerated filer

Accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes No

As of November 20, 2023, the registrant had 668,243,141 Class A Subordinate Voting Shares outstanding.

FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023

TABLE OF CONTENTS

	<u>Page</u>
PART I. FINANCIAL INFORMATION	
Item 1. Consolidated Financial Statements (unaudited)	
Condensed Consolidated Balance Sheets	1
Condensed Consolidated Statements of Operations	2
Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)	3
Condensed Consolidated Statements of Cash Flows	5
Notes to Condensed Consolidated Financial Statements (unaudited)	7
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	27
Item 3. Quantitative and Qualitative Disclosures About Market Risk	39
Item 4. Controls and Procedures	39
PART II. OTHER INFORMATION	
Item 1. Legal Proceedings	40
Item 1A. Risk Factors	41
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	41
Item 3. Defaults Upon Senior Securities	41
Item 4. Mine Safety Disclosures	41
Item 5. Other Information	41
Item 6. Exhibits	42
Signatures	43

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

4FRONT VENTURES CORP.

CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (unaudited)

As of September 30, 2023 and December 31, 2022

(Amounts expressed in thousands of U.S. dollars except for share data)

	September 30, 2023	December 31, 2022
ASSETS		
Current assets:		
Cash	\$ 2,765	\$ 14,271
Accounts receivable, net	4,208	5,448
Other receivables	222	93
Current portion of lease receivables	3,945	3,810
Inventory	17,162	18,888
Prepaid expenses and other assets	2,536	1,015
Assets related to discontinued operations	2,918	9,742
Total current assets	<u>33,756</u>	<u>53,267</u>
Property, plant, and equipment, net	39,286	34,414
Lease receivables	4,436	5,611
Intangible assets, net	27,351	29,240
Goodwill	41,807	41,807
Right-of-use assets	120,219	121,929
Deposits	2,419	4,996
Long term assets related to discontinued operations	—	53,468
TOTAL ASSETS	<u>\$ 269,274</u>	<u>\$ 344,732</u>
LIABILITIES AND SHAREHOLDERS' EQUITY		
LIABILITIES		
Current liabilities:		
Accounts payable	\$ 12,305	\$ 11,101
Accrued expenses and other current liabilities	8,958	9,101
Taxes payable	38,539	36,577
Derivative liability	16,096	—
Current portion of lease liability	1,990	2,767
Current portion of notes payable and accrued interest	8,248	9,059
Current liabilities related to discontinued operations	11,807	8,845
Total current liabilities	<u>97,943</u>	<u>77,450</u>
Convertible notes	15,677	14,843
Notes payable and accrued interest from related party	46,827	49,807
Long term notes payable	10,908	10,456
Long term accounts payable	977	962
Construction finance liability	16,000	16,000
Deferred tax liability	7,293	6,097
Lease liability	124,241	120,672
Long term liabilities related to discontinued operations	—	20,094
TOTAL LIABILITIES	<u>319,866</u>	<u>316,381</u>
SHAREHOLDERS' EQUITY (DEFICIT)		
Subordinate Voting Shares (no par value, unlimited shares authorized, 659,159,977 and 643,416,275 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively)	306,561	304,602
Additional paid-in capital	63,461	59,411
Deficit	(420,722)	(335,755)
Equity attributable to 4Front Ventures Corp.	(50,700)	28,258
Non-controlling interest	108	93
TOTAL SHAREHOLDERS' EQUITY (DEFICIT)	<u>(50,592)</u>	<u>28,351</u>
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)	<u>\$ 269,274</u>	<u>\$ 344,732</u>

See accompanying notes to condensed consolidated interim financial statements.

4FRONT VENTURES CORP.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS (unaudited)
For the Three and Nine Months Ended September 30, 2023 and 2022
(Amounts expressed in thousands of U.S. dollars except for share and per share data)

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2023	2022	2023	2022
REVENUE				
Revenue from sale of goods	\$ 20,110	\$ 25,035	\$ 67,709	\$ 70,847
Real estate income	2,892	3,065	8,747	8,981
Total revenues	23,002	28,100	76,456	79,828
Cost of goods sold	(13,722)	(11,039)	(38,884)	(35,680)
Gross profit	9,280	17,061	37,572	44,148
OPERATING EXPENSES				
Selling, general and administrative expenses	18,729	12,938	44,511	35,371
Depreciation and amortization	817	859	2,406	2,474
Share-based compensation	3,678	863	4,912	2,291
Transaction and restructuring related expenses	195	60	212	734
Total operating expenses	23,419	14,720	52,041	40,870
Income (loss) from continuing operations	(14,139)	2,341	(14,469)	3,278
Other income (expense)				
Interest income	(21)	6	—	8
Interest expense	(3,322)	(3,642)	(9,561)	(9,066)
Change in fair value of derivative liability	(11,931)	420	(11,931)	3,494
Loss on disposal	(160)	—	(160)	—
Gain on contingent consideration payable	—	—	—	2,393
Loss on litigation settlement	—	(250)	(3)	(250)
Other	(1,054)	456	(2,621)	352
Total other expense, net	(16,488)	(3,010)	(24,276)	(3,069)
Net income (loss) from continuing operations before income taxes	(30,627)	(669)	(38,745)	209
Income tax benefit (expense)	4,199	(3,321)	(818)	(9,801)
Net loss from continuing operations	(26,428)	(3,990)	(39,563)	(9,592)
Net loss from discontinued operations, net of taxes	(35,668)	(4,611)	(45,389)	(11,449)
Net loss	(62,096)	(8,601)	(84,952)	(21,041)
Net income attributable to non-controlling interest	5	5	15	15
Net loss attributable to shareholders	\$ (62,101)	\$ (8,606)	\$ (84,967)	\$ (21,056)
Basic and diluted loss per share - continuing operations	\$ (0.04)	\$ (0.01)	\$ (0.06)	\$ (0.02)
Basic and diluted loss per share - discontinued operations	\$ (0.05)	\$ (0.01)	\$ (0.07)	\$ (0.02)
Weighted average number of shares outstanding, basic and diluted	<u>653,080,343</u>	<u>639,624,851</u>	<u>647,329,688</u>	<u>632,048,250</u>

See accompanying notes to condensed consolidated interim financial statements.

4FRONT VENTURES CORP.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) (unaudited)
For the Nine Months Ended September 30, 2023 and 2022
(Amounts expressed in thousands of U.S. dollars except for share data)

	<u>Share Capital</u>		<u>Additional Paid-In Capital</u>	<u>Deficit</u>	<u>Total 4Front Ventures Corp. Shareholders' Equity (Deficit)</u>	<u>Non- Controllin g Interest</u>	<u>Total Sharehold ers' Equity (Deficit)</u>
	<u>Shares</u>	<u>Amount</u>					
Balance, December 31, 2022	643,416,275	\$ 304,602	\$ 59,411	\$ (335,755)	\$ 28,258	\$ 93	\$ 28,351
Share-based compensation	—	—	1,020	—	1,020	—	1,020
Net loss	—	—	—	(11,397)	(11,397)	5	(11,392)
Balance, March 31, 2023	643,416,275	\$ 304,602	\$ 60,431	\$ (347,152)	\$ 17,881	\$ 98	\$ 17,979
Share-based compensation	—	—	214	—	214	—	214
Shares issued for asset acquisition	2,380,952	447	—	—	447	—	447
Shares issued to settle payables	4,062,500	650	—	—	650	—	650
Net loss	—	—	—	(11,469)	(11,469)	5	(11,464)
Balance, June 30, 2023	649,859,727	\$ 305,699	\$ 60,645	\$ (358,621)	\$ 7,723	\$ 103	\$ 7,826
Share-based compensation	—	—	2,634	—	2,634	—	2,634
Warrants issued	—	—	182	—	182	—	182
Shares issued for executive compensation	9,300,250	862	—	—	862	—	862
Net loss	—	—	—	(62,101)	(62,101)	5	(62,096)
Balance, September 30, 2023	659,159,977	\$ 306,561	\$ 63,461	\$ (420,722)	\$ (50,700)	\$ 108	\$ (50,592)

See accompanying notes to condensed consolidated interim financial statements.

4FRONT VENTURES CORP.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) (unaudited)
For the Nine Months Ended September 30, 2023 and 2022
(Amounts expressed in thousands of U.S. dollars except for share data)

	<u>Share Capital</u>		<u>Additional Paid-In Capital</u>	<u>Deficit</u>	<u>Total 4Front Ventures Corp. Shareholders' Equity (Deficit)</u>	<u>Non- Controllin g Interest</u>	<u>Total Sharehold ers' Equity (Deficit)</u>
	<u>Shares</u>	<u>Amount</u>					
Balance, December 31, 2021	594,181,604	\$ 274,120	\$ 52,197	\$ (288,857)	\$ 37,460	\$ 72	\$ 37,532
Shares issued for NECC pursuant to acquisition	28,571,428	18,200	—	—	18,200	—	18,200
Share-based compensation	—	—	1,038	—	1,038	—	1,038
Conversion of notes to equity	6,235,512	3,122	—	—	3,122	—	3,122
Shares issued with exercise of warrants	88,659	50	—	—	50	—	50
Net loss	—	—	—	(5,899)	(5,899)	5	(5,894)
Balance, March 31, 2022	629,077,203	\$ 295,492	\$ 53,235	\$ (294,756)	\$ 53,971	\$ 77	\$ 54,048
Shares issued for Island pursuant to acquisition	8,783,716	6,245	—	—	6,245	—	6,245
Warrants issued for Island pursuant to acquisition	—	732	—	—	732	—	732
Share-based compensation	—	—	390	—	390	—	390
Shares issued with exercise of stock options	51,975	33	—	—	33	—	33
Net loss	—	—	—	(6,551)	(6,551)	5	(6,546)
Balance, June 30, 2022	637,912,894	\$ 302,502	\$ 53,625	\$ (301,307)	\$ 54,820	\$ 82	\$ 54,902
Shares issued for Bloom pursuant to acquisition	3,750,000	\$ 2,100	\$ —	\$ —	\$ 2,100	\$ —	\$ 2,100
Share-based compensation	—	\$ —	\$ 862	\$ —	\$ 862	\$ —	\$ 862
Shares issued with exercise of stock options	—	—	\$ —	\$ —	\$ —	\$ —	\$ —
Net loss	—	\$ —	\$ —	\$ (8,606)	\$ (8,606)	\$ 5	\$ (8,601)
Balance, September 30, 2022	641,662,894	\$ 304,602	\$ 54,487	\$ (309,913)	\$ 49,176	\$ 87	\$ 49,263

See accompanying notes to condensed consolidated interim financial statements.

4FRONT VENTURES CORP.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (unaudited)
For the Nine Months Ended September 30, 2023 and 2022
(Amounts expressed in thousands of U.S. dollars)

	Nine Months Ended	
	September 30,	
	2023	2022
CASH FLOWS FROM OPERATING ACTIVITIES		
Net loss from continuing operations	\$ (39,563)	\$ (9,592)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	4,222	4,594
Equity based compensation	4,912	2,291
Change in fair value of derivative liability	11,931	(3,494)
Accretion of lease liability	4,502	57
Loss on disposal	160	—
Change in contingent consideration payable	—	(2,393)
Accretion of debt discount	355	—
Accrued interest on convertible debenture and interest	678	872
Accrued interest on notes payable	7,261	6,483
Interest accrued - lease receivable	1,040	671
Interest on construction liability	—	1,143
Deferred taxes	1,196	(965)
Changes in operating assets and liabilities:		
Accounts receivable, net	1,240	(3,777)
Other receivables	(129)	276
Prepaid expenses and other assets	(824)	28
Inventory	1,726	(6,051)
Accounts payable	1,869	6,525
Accrued expenses and other current liabilities	(143)	4,229
Taxes payable	1,962	8,643
Deposits	977	—
Net cash provided by continuing operating activities	3,372	9,540
Net cash used in discontinued operating activities	(7,443)	(11,700)
NET CASH USED IN OPERATING ACTIVITIES	(4,071)	(2,160)
CASH FLOWS FROM INVESTING ACTIVITIES		
Cash paid for asset acquisitions and business combinations, net of cash received	(250)	(24,998)
Proceeds from note receivable	—	109
Purchases of property and equipment	(267)	(1,683)
Net cash used in continuing investing activities	(517)	(26,572)
Net cash used in discontinued investing activities	(284)	(400)
NET CASH USED IN INVESTING ACTIVITIES	(801)	(26,972)
CASH FLOWS FROM FINANCING ACTIVITIES		
Payment of contingent consideration	—	(412)
Proceeds from issuance of construction financing liability	—	16,000
Payment on construction financing liability	—	(1,143)
Notes payable issued	—	3,000
Proceeds from the exercise of warrants	—	50
Proceeds from the exercise of stock options	—	33
Repayments of notes payable	(6,634)	(5,871)
Net cash (used in) provided by continuing financing activities	(6,634)	11,657
Net cash (used in) provided by discontinued financing activities	—	—
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(6,634)	11,657

See accompanying notes to condensed consolidated interim financial statements.

4FRONT VENTURES CORP.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (unaudited)
For the Nine Months Ended September 30, 2023 and 2022
(Amounts expressed in thousands of U.S. dollars)

NET DECREASE IN CASH	(11,506)	(17,475)
CASH, BEGINNING OF PERIOD	14,271	22,435
CASH, END OF PERIOD	\$ 2,765	\$ 4,960

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

Non-cash investing and financing activities:		
Issuance of warrants for debt amendments	\$ 4,165	\$ —
Exchange of convertible debt to equity	\$ —	\$ 3,122
Issuance of equity for business combinations	\$ —	\$ 24,445
Issuance of warrants for business acquisition	\$ —	\$ 732
Issuance of equity for asset acquisition	\$ 447	\$ 2,100
Shares issued to settle payables	\$ 650	\$ —
Termination of right-of-use assets and lease liabilities	\$ —	\$ 2,020
Transfers of property and equipment from assets related to discontinued operations to continuing operations	\$ 5,498	\$ —

See accompanying notes to condensed consolidated interim financial statements.

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)

Note 1: NATURE OF OPERATIONS

4Front Ventures Corp. (“4Front” or the “Company”) exists pursuant to the provisions of the British Columbia Corporations Act. The Company operates the business through two segments: THC Cannabis and CBD Wellness. As of September 30, 2023, the Company's THC Cannabis segment consists of six dispensaries and four production and cultivation facilities across Illinois, Michigan, and Massachusetts. Also, as part of its THC Cannabis segment, the Company leases real estate and sells equipment, supplies, and intellectual property to cannabis producers in the state of Washington. The Company's CBD Wellness segment sells non-THC hemp derived products across the United States.

The unaudited condensed consolidated interim financial statements include the accounts of 4Front and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The Company has prepared these statements pursuant to the rules and regulations of the United States Securities and Exchange Commission (SEC) and U.S. GAAP. Certain information related to the organization, significant accounting policies, and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed, or omitted.

In the opinion of management, the financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. Operating results for interim periods are not necessarily indicative of results you can expect for a full year. These financials should be read in conjunction with our audited consolidated financial statements and notes thereto appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

Going Concern

As of September 30, 2023, the Company had cash of \$2.8 million and working capital deficit of \$64.2 million. The Company incurred net losses from continuing operations of \$26.4 million and \$4.0 million for the three months ended September 30, 2023 and 2022, respectively, and \$39.6 million and \$9.6 million for the nine months ended September 30, 2023 and 2022, respectively. The conditions described above raise substantial doubt with respect to the Company's ability to meet its obligations for at least one year from the issuance of these consolidated financial statements, and therefore, to continue as a going concern.

The Company plans to continue to fund its operations through cash generated from sales and is deploying its capital reserves to acquire and develop assets capable of producing additional revenues and earnings over both the immediate and near term. Capital reserves are being utilized for capital expenditures and improvements in existing facilities, product development and marketing, as well as customer, supplier and investor and industry relations. The Company has raised capital as needed, however there is no guarantee the Company will be able to continue to raise funds in the same manner it has historically.

Reclassifications

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications did not affect net loss, revenues and stockholders' equity.

Under ASC Subtopic 205-20, “*Presentation of Financial Statements - Discontinued Operations*” (“ASC Subtopic 205-20”), a component of an entity that is classified as discontinued operations is presented separately from continuing operations in the consolidated statements of operations and the consolidated statements of cash flows for all periods presented. All assets and liabilities related to such discontinued operations are presented separately in the consolidated balance sheets for all periods presented. Accordingly, the presentation of prior period balances may not agree to prior issued financial statements. See Note 16 for further information on discontinued operations.

Management's Estimates and Assumptions

The preparation of the Company's financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. We cannot predict what future laws and regulations might be passed that could have a material effect on our results of operations. We assess the impact of significant changes in laws and regulations on a regular basis and update the assumptions and estimates used to prepare our financial statements when we deem it necessary. Actual results may differ from these estimates. The most critical and subjective areas are discussed in detail in the notes in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. There have been no changes to the Company's accounting policies since the Annual Report.

Discontinued Operations

A component of an entity is identified as operations and cash flows that can be clearly distinguished, operationally and financially, from the rest of the entity. Under ASC Subtopic 205-20, "*Presentation of Financial Statements - Discontinued Operations*" ("ASC Subtopic 205-20"), a discontinued operation that is being disposed of other than by sale is considered held and used until the date of abandonment at which time it meets the criteria to be presented as discontinued operations. As of September 30, 2023, the Company's California operation, the component, was considered abandoned and are presented as discontinued operations separately from continuing operations in the consolidated balance sheets, consolidated statements of operations and the consolidated statements of cash flows for all periods presented.

New Accounting Pronouncements

Accounting Standard Updates Issued but Not Yet Adopted

In June 2022, the FASB issued ASU 2022-03, "*Fair Value Measurements - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (Topic 820)*". ASU 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. It also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. For public business entities, the ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted and the amendments in the ASU should be applied prospectively with any adjustments from the adoption of the amendments recognized in earnings and disclosed on the date of adoption. The Company is currently assessing the impact of adopting ASU 2022-03 on the consolidated financial statements.

In March 2023, the FASB issued ASU 2023-01, "*Leases (Topic 842) – Common Control Arrangements*", which require that leasehold improvements associated with common control leases be amortized by the lessee over the useful life of the leasehold improvements to the common control group (regardless of the lease term) as long as the lessee controls the use of the underlying asset. It also requires such leasehold improvements to be accounted for as a transfer between entities under common control through an adjustment to entity if, and when, the lessee no longer controls the use of the underlying asset. ASU 2023-01 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently assessing the impact of adopting ASU 2023-01 on the consolidated financial statements.

In July 2023, the FASB issued ASU 2023-03, "*Presentation of Financial Statement (Topic 205), Income Statement - Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation - Stock Compensation (Topic 718)*", to amend various SEC paragraphs in the Accounting Standards Codification to reflect the issuance of SEC Staff Accounting Bulletin No. 120, among other things. The ASU does not provide any new guidance so there is no transition or effective date associated with it. The Company is currently assessing the impact of adopting ASU 2023-03 on the consolidated financial statements.

4 FRONT VENTURES CORP.**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS***(Amounts expressed in thousands of U.S. dollars except for share and per share data)*

In October 2023, the FASB issued ASU 2023-06, "Disclosure Improvements," which incorporates certain existing or incremental disclosures and presentation requirements of SEC Regulations S-X and S-K into the FASB Accounting Standards Codification (the "Codification"). ASU 2023-06 is effective for the Company as of the effective date to remove the existing disclosure requirement from Regulations S-X and S-K. Early adoption is not permitted. The Company is currently assessing the impact of adopting ASU 2023-06 on the consolidated financial statements.

Note 2: INVENTORY

The Company's inventories are summarized in the table below:

	September 30, 2023	December 31, 2022
Raw materials - unharvested cannabis	\$ 2,726	\$ 2,431
Raw materials - harvested and purchased cannabis	6,467	6,753
Packaging and other non-finished goods	1,056	713
Work in process - manufactured and purchased extracts	1,429	3,412
Finished goods	5,484	5,579
Total inventory	\$ 17,162	\$ 18,888

Note 3: PROPERTY, PLANT, AND EQUIPMENT

Property, plant, and equipment and related depreciation are summarized in the table below:

	September 30, 2023	December 31, 2022
Land	\$ 774	\$ 774
Buildings & improvements	12,584	13,784
Construction in process	2,285	82
Furniture, equipment & other	17,025	8,963
Leasehold improvements	20,133	19,544
Total	\$ 52,801	\$ 43,147
Less: accumulated depreciation	(13,515)	(8,733)
Total property, plant, and equipment, net	\$ 39,286	\$ 34,414

Depreciation expense related to continuing operations for the three months ended September 30, 2023 and 2022 was \$0.8 million and \$0.9 million, respectively, of which \$0.6 million and \$0.7 million, respectively, is included in cost of goods sold. Depreciation expense related to continuing operations for the nine months ended September 30, 2023 and 2022 was \$2.3 million and \$2.7 million, respectively, of which \$1.8 million and \$2.1 million, respectively, is included in cost of goods sold.

Unless specifically excluded in the LI Lending note, all property, plant, and equipment is secured by LI Lending as collateral on the LI Lending note (Note 8).

On October 27, 2022, the Company amended its lease agreement for the Company's facility located in Matteson, Illinois by creating an option to increase the tenant improvement allowance for the facility between \$15.0 million and \$19.9 million. On November 10, 2022, the Company exercised its option and entered into a Second Amendment to Lease Agreement, increasing the tenant improvement allowance under the lease by \$19.9 million; extending the term of the lease to 20 years after the amendment; increasing the base rent by \$0.2 million per month (abated until April 1, 2023); and increasing the security deposit by \$2.2 million, to be funded pro rata out of draws on the tenant improvement allowance.

Refer to Note 16 for discussion of assets related to the Company's operations in California classified as discontinued operations.

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)

Note 4: INTANGIBLE ASSETS AND GOODWILL

Intangible Assets

Intangible assets and related amortization are summarized in the table below:

	<u>Licenses</u>	<u>Customer Relations hips</u>	<u>Non- Compete Agreemen ts</u>	<u>Know- How</u>	<u>Tradenames and Trademarks</u>	<u>Total</u>
December 31, 2022	\$ 25,661	\$ 2,900	\$ 249	\$ 9,700	\$ 101	\$ 38,611
Impairment	—	—	—	—	—	—
September 30, 2023 and December 31, 2022	<u>\$ 25,661</u>	<u>\$ 2,900</u>	<u>\$ 249</u>	<u>\$ 9,700</u>	<u>\$ 101</u>	<u>\$ 38,611</u>
Amortization, December 31, 2022	\$ —	\$ (2,393)	\$ (249)	\$ (6,628)	\$ (101)	\$ (9,371)
Amortization Expense	—	(434)	—	(1,455)	—	(1,889)
Impairment	—	—	—	—	—	—
30, 2023	<u>\$ —</u>	<u>\$ (2,827)</u>	<u>\$ (249)</u>	<u>\$ (8,083)</u>	<u>\$ (101)</u>	<u>\$ (11,260)</u>
December 31, 2022	<u>\$ 25,661</u>	<u>\$ 507</u>	<u>\$ —</u>	<u>\$ 3,072</u>	<u>\$ —</u>	<u>\$ 29,240</u>
September 30, 2023	<u>\$ 25,661</u>	<u>\$ 73</u>	<u>\$ —</u>	<u>\$ 1,617</u>	<u>\$ —</u>	<u>\$ 27,351</u>

During the nine months ended September 30, 2023, the Company entered into an agreement to acquire a dispensary license from Euphoria, LLC. Refer to Note 5 for further details on the transaction.

Goodwill

Balance, December 31, 2022	\$ 41,807
Adjustment to Acquisitions	—
Impairment	—
Balance, September 30, 2023	<u>\$ 41,807</u>

Impairment of Intangible Assets and Goodwill

Goodwill as of September 30, 2023 is related to the THC Cannabis segment in which there is no accumulated impairment within this segment. Goodwill related to the CBD Wellness segment has an accumulated impairment charge of \$13.4 million, which represented the entire balance and occurred during the year ended December 31, 2020. As of September 30, 2023 and December 31, 2022, all goodwill and intangibles are attributable to the THC Cannabis segment.

Goodwill and infinite lived assets are assessed on an annual basis for impairment, or more frequently, if circumstances indicate an impairment to the carrying value may have occurred. As of September 30, 2023, the Company believes the carrying amounts of the long-lived assets, including finite-lived intangible assets (licenses), are recoverable and there were no events or circumstances that indicated impairment for any assets outside of California. However, if adverse events were to occur or circumstances were to change indicating the carrying amount of such assets may not be fully recoverable, the assets would be reviewed for impairment.

Refer to Note 16 for discussion of intangible assets and goodwill related to the Company's operations in California classified as discontinued operations.

Note 5: ASSET ACQUISITIONS

Euphoria, LLC

On March 27, 2023, the Company entered into a Membership Interest Purchase Agreement to acquire 100% of the issued and outstanding equity interests in Euphoria, LLC ("Euphoria") for a total purchase price of \$4.5 million to be paid in cash, promissory notes, and Class A Subordinate Voting Shares. Euphoria holds a conditional adult use dispensary license in the state of Illinois which shall convert to a state license upon regulatory approval. The transfer of the license is subject to regulatory approval. As of September 30, 2023, the Company has paid \$0.3 million in cash and issued 2,308,952 Class A Subordinate Voting Shares valued at \$0.4 million based on the closing stock price of the SVS on the issuance date. In certain events as defined in this agreement, such as, but not limited to the inability to obtain regulatory approval, all consideration paid by the Company to the sellers are refundable. The remaining consideration will be due upon regulatory approval at the closing date. In the event of termination by the Company under certain circumstances, the Company shall pay a breakup fee of \$3.5 million to the sellers, less any portion of the purchase price already paid. Conversely, in the event of termination by the sellers under certain circumstances, the sellers shall pay a breakup fee of \$3.5 million to the Company.

Note 6: DERIVATIVE LIABILITY

In November 2022, the warrants issued in connection with the November 2020 private placement had expired unexercised and, accordingly, the balance of derivative liabilities was nil as of December 31, 2022.

In connection with the amendment of the senior secured debt with LI Lending LLC in July 2023, the Company issued 100,358,824 warrants on August 10, 2023 wherein each warrant shall be exercisable into one (1) Subordinate Voting Share at an exercise price of \$0.17 through May 1, 2026. If 4Front obtains a bona fide offer from a third party to refinance the loan within six months from the amendment date, the lender will have the option to match the proposed terms of the offer or keep the loan in force; upon exercise of either option, the lender's warrant coverage will be reduced to 30% of the loan balance divided by the exercise price as of the current maturity date. If 4Front obtains permitted secured debt senior to the loan up to \$8 million, 75% of the warrants will become exercisable by cashless exercise. If 4Front obtains permitted secured debt senior to the loan in excess of \$8 million (up to the \$10 million maximum), 100% of the warrants will become exercisable by cashless exercise. The warrants met the criteria in ASC 480 due to the variability of the number of issuable shares, and are therefore classified as liabilities at fair value with changes being reported through the statement of operations. See Note 8 for further information on the July 2023 amendment.

The fair value of the warrants classified as liabilities was determined using the Black-Scholes simulation model based on Level 3 inputs on the fair value hierarchy. The following assumptions were used for the periods presented:

	Issuance Date	September 30, 2023
Share Price	\$ 0.10	\$ 0.25
Exercise Price	\$ 0.17	\$ 0.17
Expected Life	2.7 years	2.6 years
Annualized Volatility	84.5 %	88.8 %
Risk-Free Annual Interest Rate	4.5 %	4.8 %

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)

For the three and nine months ended September 30, 2023 and 2022, changes in fair value of the derivative liabilities measured on a recurring basis using significant unobservable inputs (Level 3) were as follows:

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2023	2022	2023	2022
Balance, beginning of period	\$ —	\$ 428	\$ —	\$ 3,502
Issuance of warrants	4,165	—	4,165	—
Change in fair value of derivative liability	11,931	(420)	11,931	(3,494)
Balance, end of period	<u>\$ 16,096</u>	<u>\$ 8</u>	<u>\$ 16,096</u>	<u>\$ 8</u>

See Note 10 for warrants classified within equity.

Note 7: LEASES

New Lease Agreement

On August 23, 2023, the Company entered into a lease agreement for a third dispensary location in Illinois. Within five days of the agreement execution, the premise was available to the Company to begin leasehold improvements. The Company funded a security deposit with rent abated for the first nine calendar months following the rent commencement date. As of September 30, 2023, The Company recognized an initial right of use asset and lease liability of \$1.2 million in connection with this agreement.

Modification of Lease Agreement

On July 7, 2023, the Company amended its lease agreement for the cultivation and production facility in Matteson, Illinois to apply a portion of the security deposit to pay one-half of the monthly base rent for the four month period through November 30, 2023; to defer payment of the \$2.2 million increase in security deposit to be funded as draws on the tenant improvement allowance through November 30, 2023; and to make pro rata payments of such deferred payments equal to 1/12 of the aggregate amount, concurrently with monthly base rent installments, for the twelve month period commencing January 1, 2024. There was no modification to the lease accounting as a result of this amendment to the timing of payments of the refundable security deposit.

Discontinued Operations

During the fiscal quarter ended September 30, 2023, the Company ceased its cultivation and production operations in the state of California (together, the "California operations") as reported under the THC Cannabis segment. As a result, all prior year right-of-use assets and lease liabilities were reclassified as assets related to discontinued operations and liabilities related to discontinued operations, respectively in prior periods reflected. As of September 30, 2023, the right-of-use assets and lease liabilities related to the discontinued operations were written off.

The Company as a Lessor:

Lease income for operating and direct financing leases for the periods presented are as follows:

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2023	2022	2023	2022
Real estate income:				
Operating leases	\$ 2,318	\$ 2,424	\$ 6,952	\$ 6,952
Direct financing leases	574	641	1,795	2,029
Total real estate income	<u>\$ 2,892</u>	<u>\$ 3,065</u>	<u>\$ 8,747</u>	<u>\$ 8,981</u>

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)

The Company leases buildings in Olympia, Washington and Elk Grove, Illinois that are subleased or partly subleased to a third party. The subleases are classified as operating leases under ASC 842. The underlying assets are presented in the condensed consolidated balances sheets as follows:

	September 30, 2023	December 31, 2022
Right-of-use assets	\$ 25,465	\$ 26,133
Current portion of lease liability	\$ 290	\$ 295
Long-term portion of lease liability	\$ 22,302	\$ 22,078

The Company also leases a building in Elma, Washington that is subleased to a third party. This sublease is classified as a finance lease. A reconciliation of the lease receivables is as follows:

	September 30, 2023	December 31, 2022
Balance, beginning of period	\$ 9,421	\$ 10,378
Interest	1,795	2,673
Lease payments transferred to accounts receivable	(2,835)	(3,630)
Balance, end of period	8,381	9,421
Less current portion	(3,945)	(3,810)
Long-term lease receivables	\$ 4,436	\$ 5,611

Note 8: NOTES PAYABLE AND CONVERTIBLE NOTES

The Company's notes payable and convertible notes are as follows:

Terms	September 30, 2023	December 31, 2022
Secured promissory notes dated May 10, 2019, as subsequently amended, with a related party which mature on May 1, 2026 and bear interest at a rate of 16.5% per annum through May 1, 2024 and 12% per annum thereafter	\$ 46,827	\$ 49,807
Convertible promissory note dated October 6, 2021, which mature on October 6, 2024 and bear interest at a rate of 6% per annum ⁽³⁾	15,677	14,843
Unsecured convertible promissory note at \$0.50 per share due December 18, 2023 at 12% per annum through May 2023 and 14% per annum through December 2023 ⁽³⁾	3,981	3,554
Promissory note issued for the acquisition of NECC due January 7, 2023 at 10% per annum	—	519
Promissory note issued for the acquisition of Island due October 25, 2026 at 6% per annum	10,880	10,431
Secured promissory note due February 28, 2023 at 1.5% monthly interest for three months and 2% monthly interest for three months ⁽¹⁾	2,561	3,230
Unsecured promissory note due November 30, 2024, monthly interest payments at 12% per annum through September 2023 and 11% per annum through November 2024 ⁽²⁾	1,705	1,730
Various	29	51
Total Notes Payable and Convertible Notes	\$ 81,660	\$ 84,165

(1) The Company was in default of the secured promissory note as of September 30, 2023. Effective October 10, 2023, management has renegotiated the terms of the promissory note and extended the term of the lender note to January 1, 2024 in exchange for a loan extension fee of \$0.1 million issued in warrants. Refer to Note 19 for further information.

(2) The Company entered into an amendment of this promissory note in September 2023 to reduce the interest rate to 11% and extend the maturity date to November 30, 2024.

(3) Refer to Note 19 for further information.

LI Lending LLC

On May 10, 2019, the Company entered into a loan agreement with LI Lending LLC, a related party, for \$50.0 million, of which \$43.0 million was drawn as of September 30, 2023 in two amounts: (i) \$35.0 million bearing interest at a rate of 10.25% and (ii) \$10.0 million bear interest at a rate of 12.25%. The loan matures on May 10, 2024 upon the Company shall pay an exit fee of 20% of the remaining principal balance.

In April 2020, the loan was amended to release certain assets previously held as collateral and to make principal prepayments totaling \$2.0 million applied to the initial \$35.0 million amount, decreasing the principal balance to \$33.0 million. In December 2020, the loan was amended to increase the interest rate by 2.5% of which payments of the incremental interest were paid-in-kind until January 1, 2022. The Company was still required to make interest-only payments monthly of 10.25% on the initial \$33.0 million and 12.25% on the final \$10.0 million of the loan until January 1, 2022, when monthly interest rates were increased to 12.75% for the initial \$35.0 million and 14.75% for the final \$10.0 million for the remaining term.

In July 2023, the Company entered into the First Amendment to the loan agreement with LI Lending LLC to extend the maturity date of the related party loan to May 1, 2026, to reduce the interest rate to 12.0% per annum beginning May 1, 2024, and to expand the amount of third-party financings allowed under the loan agreement. As compensation for the amendment, the Company shall pay an extension fee of \$0.5 million payable in cash on May 1, 2024. In addition, the Company issued 100,358,824 warrants on August 10, 2023 in accordance with this amendment. See Note 6 for further information regarding the fair value of the warrants. The amendment to the related party loan was not deemed to be a substantial modification under ASC Subtopic 470-50. As a result of the modification, the Company recorded an additional debt discount of \$4.7 million related to the extension fee and the fair value of the warrants.

For the three months ended September 30, 2023 and 2022, the Company recognized accrued interest expense of \$2.0 million and \$2.5 million, respectively, on the related party loan and made \$1.6 million and \$2.2 million, respectively, in payments of principal and interest to the related party. For the nine months ended September 30, 2023 and 2022, the Company recognized accrued interest expense of \$5.8 million and \$5.8 million, respectively, on the related party loan and made \$4.8 million and \$4.7 million, respectively, in payments of principal and interest to the related party. See Note 13 for further discussion of this related party transaction.

October 2021 Convertible Note

On October 6, 2021, the Company entered into a convertible promissory note for \$15.0 million that is exercisable into Class A Subordinate Voting Shares for \$1.03 per share at any time at the option of the holder. The notes bear interest at 6% per annum and mature on October 6, 2024 upon which any remaining balance is payable in cash. All accrued and unpaid interest is payable in cash on an annual basis beginning on October 6, 2022. As of September 30, 2023, payments of principal and interest totaling \$1.1 million have been made for this loan. As of September 30, 2023 and December 31, 2022, the unamortized discount balance related to the October 2021 Convertible Note was \$0.2 million and \$0.4 million, respectively, with a remaining amortization period of 1.00 year and 1.75 years, respectively. For the nine months ended September 30, 2023 and 2022, the Company recognized interest expense of \$0.7 million and \$0.3 million, respectively, and accretion of debt discount of \$0.2 million and \$0.1 million, respectively, related to the October 2021 Convertible Note.

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)

Note 9: SHAREHOLDERS' EQUITY

The Company has authorized an unlimited number of Class A Subordinate Voting Shares (“SVS”) and Class C Multiple Voting Shares (“MVS”), all with no par value.

All share classes are included within share capital in the consolidated statements of shareholders’ equity on an as-converted basis. Each share class is entitled to notice of and to attend any meeting of the shareholders, except a meeting of which only holders of another particular class of shares will have the right to vote. All share classes are entitled to receive dividends, as and when declared by the Company, on an as-converted basis, and no dividends will be declared by the Company on any individual class unless the Company simultaneously declares or pays dividends on all share classes. No subdivision or consolidation of any share class shall be made without simultaneously subdividing or consolidating all share classes in the same manner.

Voting shares activity for the periods presented is summarized as follows:

	Class A Subordinate Voting Shares	Class C Multiple Voting Shares	Total
Balance, December 31, 2022	642,140,067	1,276,208	643,416,275
Share capital issuances	15,743,702	—	15,743,702
Balance, September 30, 2023	657,883,769	1,276,208	659,159,977

Class A Subordinate Voting Shares

Holders of Class A Subordinate Voting Shares are entitled to one vote in respect of each SVS.

Class C Multiple Voting Shares

Holders of Class C Multiple Voting Shares are entitled to 800 votes in respect of each MVS. One MVS can convert to one SVS but are not convertible until the aggregate number of MVS held by the Initial Holders (being the MVS holders on their initial issuance) are reduced to a number which is less than 50% of the aggregate number of MVS held by the Initial Holders on the date of completion of the business combination with Cannex.

Series	September 30, 2023
Class A - Subordinate Voting Shares	657,883,769
Class C - Multiple Voting Shares	1,276,208
Total shares outstanding	659,159,977

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)

Note 10: WARRANTS

A reconciliation of the beginning and ending balance of share purchase warrants outstanding is as follows:

	Number of Warrants	Exercise Price
Balance, December 31, 2022	6,352,278	\$ 0.82
Issued	1,375,000	\$ 0.13
Expired	(2,227,303)	\$ 0.67
Balance, September 30, 2023	<u>5,499,975</u>	\$ 0.70

As of September 30, 2023, the Company had the following warrants outstanding:

Warrants Outstanding	Exercise Price	Expiration Date
2,999,975	\$ 1.00	April 13, 2024
625,000 * C\$	0.80	October 6, 2024
500,000 * C\$	0.80	October 6, 2025
625,000 C\$	0.23	May 10, 2027
750,000	\$ 0.10	September 1, 2027
<u>5,499,975</u>		

*Represents warrants that were exercisable as of September 30, 2023.

Refer to Note 6 for warrants classified as liability.

Note 11: SHARE-BASED COMPENSATION

The Company adopted two equity incentive plans where the Company may grant Class A stock options. Under the terms of the plans, the maximum number of stock options which may be granted are a total of 10% of the number of shares outstanding assuming conversion of all shares to SVS. The exercise price for stock options issued under the plans will be set by the Compensation Committee of the Board of Directors but will not be less than 100% of the fair market value of the Company's shares on the grant date. Stock options have a maximum term of 10 years from the date of grant. Stock options vest at the discretion of the Board.

As of September 30, 2023, the Company had 26,943,098 options exercisable and 84,870,266 options outstanding, with exercise prices ranging from C\$0.10 to C\$1.63. The following table summarizes the Company's stock option activity and related information:

	Number of Options	Weighted Average Price CAD\$	Weighted Average Years
Balance, December 31, 2022	75,626,960	\$ 0.86	3.46
Granted	60,724,666	\$ 0.20	3.42
Forfeited/Expired	(51,481,360)	\$ 0.83	—
Balance, September 30, 2023	<u>84,870,266</u>	\$ 0.38	4.52

During the three months ended September 30, 2023 and 2022, the Company recognized share-based compensation of \$2.6 million and \$0.9 million, respectively. During the nine months ended September 30, 2023 and 2022, the Company recognized share-based compensation of \$3.9 million and \$2.3 million, respectively. In determining the amount of share-based compensation during the periods ended September 30, 2023 and 2022, the Company used the Black-Scholes option pricing model to establish the fair value of options granted with the following key assumptions:

	Nine Months Ended September 30,	
	2023	2022
Risk-Free Interest Rate	4.02 %	3.62 %
Expected Life	3.42 years	3.50 years
Expected Annualized Volatility	86.62 %	89.83 %
Forfeiture rate	— %	— %
Expected Dividend Yield	— %	— %

Restricted Share Units

On July 27, 2023, the Company issued a total of 9,853,830 restricted share units ("RSUs"), at a deemed issue price of C\$0.165 based on the closing price of its Subordinate Voting Shares, to certain officers and employees of the Company in payment of fiscal year-end 2022 bonus entitlements. The RSUs are fully vested as of the grant date and expire upon the earlier of 18 months following the grant date or the occurrence of certain events. As of September 30, 2023, the Company recognized share-based compensation of \$1.2 million for these fully vested RSU grants.

Note 12: INCOME TAXES

The following table summarizes the Company's income tax expense:

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2023	2022	2023	2022
Net loss from continuing operations before income taxes	\$ (30,627)	\$ (669)	\$ (38,745)	\$ 209
Income tax benefit (expense)	\$ 4,199	\$ (3,321)	\$ (818)	\$ (9,801)

The Company has computed its provision for income taxes under the discrete method which treats the year-to-date period as if it were the annual period and determines the income tax expense or benefit on that basis. The discrete method is applied when application of the estimated annual effective tax rate is impractical because it is not possible to reliably estimate the annual effective tax rate. At this time, there is a high degree of uncertainty in estimating the Company's annual pre-tax income and significant non-deductible expenses so the Company cannot reliably estimate the annual effective tax rate.

Due to its cannabis operations, the Company is subject to the limitations of the U.S. Internal Revenue Code ("IRC") Section 280E under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E. Therefore, the effective tax rate can be highly variable and may not necessarily correlate with pre-tax income and provides for effective tax rates that are well in excess of statutory tax rates.

The Company files income tax returns in the U.S. and various state jurisdictions and is subject to examination of its income tax returns by tax authorities in these jurisdictions who may challenge any item on these returns. The corporate statute of limitations for these jurisdictions remains open for the 2019 tax year to the present. Prior to July 31, 2019, the Company was treated as a partnership for income tax purposes and tax income and losses generated from operations were passed through to the Company's individual members.

Note 13: RELATED PARTIES

LI Lending LLC

Linchpin Investors LLC (“Linchpin”), a subsidiary of the Company, and LI Lending LLC (“LI Lending”) entered into a Construction Loan Agreement dated May 10, 2019, as amended, whereby Linchpin received an up-to \$50.0 million loan from LI Lending, of which \$43.0 million was drawn as of September 30, 2023. Mr. Gontmakher, the CEO of the Company, and Roman Tkachenko, a director of the Company, each hold a 14.28% ownership interest in LI Lending. \$51.6 million of the loan advanced includes the notes payable and accrued interest less debt discount of \$4.7 million that was outstanding as of September 30, 2023. Of the \$46.8 million outstanding at September 30, 2023, \$8.0 million represents interest accrued through September 30, 2023. See Note 8 for details on the outstanding note payable.

In July 2023, the related party loan was amended wherein while the debt is outstanding, if the Company unilaterally removes Mr. Gontmakher as its Chief Executive Officer or Karl Chowscano as its President without either cause or lender consent, the maturity date of the loan will be accelerated to the date that is 30 days after the first unilateral removal. In addition, the exit fee of \$9.0 million was replaced with deferred interest of \$9.2 million which will be added to the principal of the promissory note on May 1, 2024, for a total payable at maturity of \$51.7 million. Refer to Note 8 for additional amendment terms.

Note 14: CONTINGENCIES

(a) Cannabis Industry

While marijuana is legal under the laws of several U.S. states (with varying restrictions), the United States Federal Controlled Substances Act classifies all “marijuana” as a Schedule I drug, whether for medical or recreational use. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. As such, there is an inherent risk related to the federal government’s position on cannabis. There is additional risk associated with the Company’s business in cannabis that third-party service providers could suspend or withdraw services and regulatory bodies could impose certain restrictions on the issuer’s ability to operate in the U.S. As of September 30, 2023, Company has not estimated a potential liability related to the possible enforcement of laws against the medical cannabis industry.

(b) Legal Matters

From time to time, the Company may be involved in certain disputes arising in the ordinary course of business. Such disputes, taken in the aggregate, are not expected to have a material adverse effect on the Company. There are also no proceedings in which any of the Company’s directors, officers, or affiliates is an adverse party or has a material interest adverse to the Company’s interest.

On January 26, 2022, Savills, Inc. sued the Company in the U.S. District Court for the Southern District of New York. That lawsuit alleged the Company had breached an alleged agreement with Savills under which the Company was allegedly required to pay Savills a percentage of savings realized under certain incentive programs offered in some jurisdictions, which Savills would assist the Company in obtaining. Savills claimed damages of approximately \$19.4 million in connection with its claim that it obtained benefits for the Company allegedly valued at over \$129.0 million. The Company denied these allegations, denied the Company had obtained such benefits, disputed Savills’ characterization of the facts, and denied liability. The Company filed a counterclaim against Savills alleging breach of contract by Savills. On August 3, 2022, the parties reached a confidential settlement in principle and agreed to dismissal of all claims, which was finalized on September 12, 2022 and required the Company to pay \$0.25 million in five monthly installments beginning in October 2022. In addition to this initial payment, there is a portion of the settlement that is contingent on future tax savings. As of September 30, 2023, this additional contingent amount is not reasonably estimable.

On May 9, 2023, Florival LLC (“Florival”) sued the Company in the California Superior Court for the County of Santa Cruz. The lawsuit alleged the Company had breached an agreement with Florival under which Company subsidiary Island Global Holdings, Inc. (“Island”) agreed to purchase the membership interests of licensed cannabis cultivator Gold Coast Gardens, LLC. Florival claimed damages of \$0.85 million. The Company denied it had any direct liability under the agreement, which was executed two years before the Company’s acquisition of Island and asserted an unclean hands defense on behalf of both the Company and Island based on Florival’s inequitable conduct during the litigation. On November 7, 2023, the court entered summary judgment against the Company and Island. The Company and Island intends to appeal the decision. Management has accrued \$0.85 million related to this matter as of September 30, 2023.

On September 14, 2023, Teichman Enterprises, Inc. (“Teichman”) sued Company subsidiary 4Front California Capital Holdings, Inc. (“4Front CA”) in the California Superior Court for the County of Los Angeles. The lawsuit alleged 4Front CA had breached a lease with Teichman for 4Front CA’s facility in Commerce, California by failing to pay rent due under the lease. Teichman sought possession of the property and damages of \$0.6 million. 4Front CA denied the allegations, but vacated the facility. Trial is set for January 2024. Management has accrued \$0.6 million related to this matter as of September 30, 2023.

On September 29, 2023, Teichman Enterprises, Inc. sued 4Front CA and the Company in the Superior Court for the County of Los Angeles. The lawsuit alleged the Company had breached a lease agreement with Teichman under which the Company entered into a 10 year lease commitment ending on January 31, 2029, and that the Company breached its guarantee of the lease. Teichman has alleged total rent owed under the lease agreement is \$13.4 million in addition to a license fee of \$1.0 million and additional damages. Total damages sought from Teichman under the lease contracts is \$15.5 million. 4Front CA and the Company denied the allegations in the complaint, and denied that Teichman was entitled to the full amount of damages claimed due to Teichman's obligation to mitigate. Based on management's review of case, the Company has accrued \$2.0 million associated with this legal liability as of September 30, 2023.

Note 15: FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT

The fair value of the Company's cash, accounts receivable, other receivables, accounts payable and accrued expenses approximates carrying value due to their short-term nature. The Company's lease receivables, long term accounts payable and construction finance liability, convertible notes payable, and notes payable approximate fair value due to the instruments bearing market rates of interest. These measurements were identified as Level 1 measurements, due to the proximity of fair value to carrying values. The fair value of stock options granted were estimated based on a Black-Scholes model. The estimated fair value of the derivative liabilities, which represent warrants classified as liabilities, represent Level 3 measurements.

There were no transfers between fair value levels for the three and nine months ended September 30, 2023 and the year ended December 31, 2022.

(a) Financial Risk Management

The Company is exposed in varying degrees to a variety of financial instruments related risks. The Company's board of directors mitigate these risks by assessing, monitoring and approving the Company's risk management processes.

(b) Credit Risk

Credit risk is the risk of loss associated with counterparty's inability to fulfill its payment obligations. The Company's credit risk is primarily attributable to cash, accounts receivable, lease receivables, and other receivables. The risk to cash deposits is mitigated by holding these instruments with regulated financial institutions. Accounts receivable, lease receivables, and other receivables credit risk arises from the possibility that principal and interest due may become uncollectible. The Company mitigates this risk by managing and monitoring the underlying business relationships.

The Company maintains cash with federally insured financial institutions. As of September 30, 2023 and December 31, 2022, the Company exceeded federally insured limits by \$0.1 million and \$10.1 million, respectively. The Company has historically not experienced any losses in such accounts. As of September 30, 2023 and December 31, 2022, the Company held an immaterial amount of cash in a Canadian account that is denominated in C\$.

As of September 30, 2023 and December 31, 2022, the maximum credit exposure related to the carrying amounts of accounts receivable, other receivable, and lease receivables was \$12.8 million and \$15.0 million, respectively.

(c) Liquidity Risk

The Company manages liquidity risk through the management of its capital structure. The Company's approach to managing liquidity is to raise sufficient capital to settle obligations and liabilities when due. The Company has raised capital as needed, however there is no guarantee the company will be able to continue to raise funds in the same manor it has historically.

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)

The Company has the following gross contractual obligations as of September 30, 2023, which are expected to be payable in the following respective periods:

	Less than 1 year	1 to 3 years	3 to 5 years	Greater than 5 years	Total
Accounts payable and accrued liabilities	\$ 21,263	\$ 977	\$ —	\$ —	\$ 22,240
Convertible notes, notes payable and accrued interest	8,248	62,532	10,880	—	81,660
Construction finance liability	—	16,000	—	—	16,000
Total	\$ 29,511	\$ 79,509	\$ 10,880	\$ —	\$ 119,900

(d) Foreign Exchange Risk

The Company is exposed to exchange rate fluctuations between United States and Canadian dollars. The Company's share price is denominated in Canadian dollars. If the Canadian dollar declines against the United States dollar, the United States dollar amounts available to fund the Company through the exercise of stock options or warrants will be reduced. The Company also has bank accounts with balances in Canadian dollars. The value of these bank balances if converted to U.S. dollars will fluctuate. While the Company maintains a head office in Canada where it incurs expenses primarily denominated in Canadian dollars, such expenses are a small portion of overall expenses incurred by the Company. The Company does not have a practice of trading derivatives and does not engage in "natural hedging" for funds held in Canada.

Note 16: DISCONTINUED OPERATIONS

During the fiscal quarter ended September 30, 2023, the Company ceased its cultivation and production operations in the state of California (together, the "California operations") as reported under the TCH Cannabis segment. The Company concluded that the abandonment of its California operations represented a strategic shift and thus all assets and liabilities to the operations within the state of California were classified as discontinued operations. Long-lived assets related to the California operations ceased to be used as of September 30, 2023 and thus considered disposed of other than by sale as of September 30, 2023. The assets associated with the California operations were measured at the lower of their carrying amount or fair value less costs to sell. During the three and nine months ended September 30, 2023, the Company recognized a loss on disposal of \$12.7 million for the net carrying value of the assets as of the disposition date which was determined as the book value less direct costs to sell and an impairment charge of \$12.9 million for the write-off of its intangible assets and goodwill. The Company does not have significant continuing involvement with the California operations outside of the contract liabilities of \$2.3 million and the litigation matters disclosed in Note 14.

Revenue and expenses, gains or losses relating to the discontinuation of California operations were eliminated from profit or loss from the Company's continuing operations and are shown as a single line item in the consolidated statements of operations for all periods presented.

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)

The operating results of the discontinued operations are summarized as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
REVENUE				
Revenue from sale of goods	\$ 1,566	\$ 4,032	\$ 9,033	\$ 6,791
Real estate income	260	342	411	342
Total revenues	1,826	4,374	9,444	7,133
Cost of goods sold	(6,666)	(6,388)	(21,992)	(10,464)
Gross profit	(4,840)	(2,014)	(12,548)	(3,331)
OPERATING EXPENSES				
Selling, general and administrative expenses	1,310	2,167	4,703	6,047
Depreciation and amortization	42	161	189	516
Transaction and restructuring related expenses	942	—	942	1,335
Impairment of goodwill and intangible assets	12,856	—	12,856	—
Total operating expenses	15,150	2,328	18,690	7,898
Loss from operations	(19,990)	(4,342)	(31,238)	(11,229)
Other income (expense)				
Interest expense	—	(3)	(32)	(7)
Loss on disposal	(12,747)	—	(12,747)	—
Other	(2,930)	(266)	(1,371)	(213)
Total other income (expense), net	(15,677)	(269)	(14,150)	(220)
Net loss from discontinued operations before income taxes	(35,667)	(4,611)	(45,388)	(11,449)
Income tax expense	(1)	—	(1)	—
Net loss on discontinued operations	\$ (35,668)	\$ (4,611)	\$ (45,389)	\$ (11,449)

4 FRONT VENTURES CORP.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Amounts expressed in thousands of U.S. dollars except for share and per share data)

The carrying amounts of assets and liabilities in the disposal group are summarized as follows:

	September 30, 2023	December 31, 2022
Carrying amount of the assets included in discontinued operations:		
Current assets:		
Cash	\$ 122	\$ 919
Accounts receivable, net	326	1,943
Other receivables	17	(16)
Inventory	372	6,704
Prepaid expenses and other assets	—	192
Total current assets ⁽¹⁾	<u>837</u>	<u>9,742</u>
Property, plant, and equipment, net	1,302	22,492
Intangible assets, net	760	1,687
Goodwill	—	12,148
Right-of-use assets	—	16,522
Deposits	19	619
Total non-current assets ⁽¹⁾	<u>2,081</u>	<u>53,468</u>
TOTAL ASSETS OF THE DISPOSAL GROUP	<u>\$ 2,918</u>	<u>\$ 63,210</u>
Carrying amount of the liabilities included in discontinued operations:		
Current liabilities:		
Accounts payable	3,527	1,600
Accrued expenses and other current liabilities	5,542	5,164
Taxes payable	72	—
Current portion of contract liabilities	328	369
Current portion of lease liability	—	1,712
Total current liabilities ⁽¹⁾	<u>9,469</u>	<u>8,845</u>
Long term notes payable	8	—
Long term accounts payable	330	400
Contract liabilities	2,000	2,000
Deferred tax liability	—	2,181
Lease liability	—	15,513
Total non-current liabilities ⁽¹⁾	<u>2,338</u>	<u>20,094</u>
TOTAL LIABILITIES OF THE DISPOSAL GROUP	<u>\$ 11,807</u>	<u>\$ 28,939</u>

(1) The assets and liabilities of the disposal group are classified as current on the consolidated balance sheets as of September 30, 2023 because it is probable that the sale or disposal other than by sale will occur within one year.

4 FRONT VENTURES CORP.**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS***(Amounts expressed in thousands of U.S. dollars except for share and per share data)***Note 17: SEGMENT INFORMATION**

As of September 30, 2023, the Company had two reportable segments as follows:

- THC Cannabis – Cultivation, manufacturing, and distribution of THC cannabis; and
- CBD Wellness – Sale of CBD products to third-party consumers.

The below table presents financial results of each segment for the three and nine months ended September 30, 2023 and 2022, as well as total assets as of September 30, 2023 and December 31, 2022:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
<i>Net Revenues</i>				
THC Cannabis	\$ 22,840	28,276	\$ 75,815	\$ 79,495
CBD Wellness	162	(176)	641	333
Total Net Revenues	\$ 23,002	28,100	\$ 76,456	\$ 79,828
<i>Net (Income) Loss Attributable to Shareholders</i>				
THC Cannabis	\$ 18,311	(5,172)	\$ 21,622	\$ (2,659)
CBD Wellness	51	(51)	62	(170)
Corporate	8,066	9,213	17,879	12,421
Total Net Loss From Continuing Operations	\$ 26,428	3,990	\$ 39,563	\$ 9,592
			September 30, 2023	December 31, 2022
<i>Assets</i>				
THC Cannabis			\$ 268,211	\$ 343,410
CBD Wellness			400	625
Corporate			663	697
Total Assets			\$ 269,274	\$ 344,732

Note 18 SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

The below table presents detailed information of selling, general and administrative expenses for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
Rent Expenses	\$ 4,883	\$ 3,964	\$ 13,591	\$ 9,787
Salaries and Benefits	4,646	5,324	13,610	13,843
Security Expenses	343	244	1,029	834
Other Business Taxes	508	14	914	392
Bad Debt Expense	6,523	(110)	6,852	—
Professional Services	790	498	2,781	2,594
Other General and Administrative Expenses	1,036	3,004	5,734	7,921
Total Selling, General, and Administrative	\$ 18,729	\$ 12,938	\$ 44,511	\$ 35,371

Note 19: SUBSEQUENT EVENTS

The Company has evaluated subsequent events through November 20, 2023, which is the date these condensed consolidated interim financial statements were issued, and has concluded that the following subsequent events have occurred that would require recognition in the condensed consolidated financial statements or disclosure in the notes to the condensed consolidated interim financial statements.

On October 2, 2023, the Company amended the unsecured convertible promissory note with Healthy Pharms Inc. wherein the interest rate was amended to 12.0% per annum and the maturity date was extended to December 18, 2024. Beginning January 15, 2024, the Company shall make monthly cash payments of \$50,000 through the maturity date. In November 2023, the Company issued 10,359,372 Class A Subordinate Voting Shares to the noteholder to settle \$1,992,187 of the promissory note.

On October 6, 2023, the Company amended the October 2021 Convertible Note wherein payment of interest shall be deferred and become due and payable upon the earlier of the maturity date, a change of control, or event of default under the existing agreement terms. In addition, the outstanding balance, including any deferred interest payments, shall accrue interest at a rate of 10.0% per annum through maturity. The conversion price was amended to \$0.23 per share.

On October 10, 2023, the Company amended the Promissory Note Purchase Agreement with HI 4Front, LLC and Navy Capital Green Fund, LP wherein the maturity date was extended to January 1, 2024. As consideration for the amendment, the Company paid an extension fee of C\$65,000 in the form of 1,283,425 share purchase warrants, wherein each warrant is exercisable into one (1) Subordinate Voting Share at an exercise price of US\$0.20 and expire on October 17, 2027.

On October 13, 2023, the Company entered into a senior secured credit facility agreement for an aggregate principal up to \$10.0 million in which a term loan in the amount of \$6.0 million was drawn on the closing date and a second tranche of \$4.0 million is available to be drawn through July 13, 2024. The term loans accrue interest paid monthly in arrears at a rate equal to the greater of (a) the sum of the prime rate and 7.0% and (b) 15.5% per annum. The term loans mature on December 1, 2023 and include extension terms under certain circumstances no further than September 30, 2026. For each term loan, the Company shall pay an origination fee equal to 7.0% of the principal amount of the term loan upon issuance. In addition, the Company shall pay a commitment fee on the undrawn second tranche which shall accrue at a rate per annum of 2.0% through the earlier of July 13, 2024 and the date on which the maximum facility amount is drawn. The Company may prepay the term loans, in whole or in part, at any time subject to the prepayment fee based on the date of the prepayment. Further, the Company shall pay an exit fee of \$1.4 million upon the earlier of the maturity date or the date on which the obligations are paid in full. The term loans shall be secured by senior liens on all assets of the Company and borrowing subsidiaries.

The agreement contains financial covenants that (a) require the Company to have minimum liquidity of at least \$3.0 million beginning December 31, 2023, (b) have a fixed charge coverage ratio of no less than 1.10 to 1:00 beginning June 30, 2024 and (c) have a consolidated leverage ratio of no more than 3.00 to 1:00 beginning June 30, 2024. The Loan Agreement contains additional covenants that, among other things, limit the ability of the Company and its subsidiaries to incur certain additional debt and liens, pay certain dividends or make other restricted payments, make certain investments, make certain dispositions and enter into certain transactions with affiliates.

The proceeds of the term loans shall be used only to acquire and build out new or improve existing dispensaries in Illinois, resolve certain liabilities, and pay expenses related to the transaction as defined in the agreement.

On November 13, 2023, in connection with the \$10.0 million senior secured credit facility agreement, the Company issued 15,900,000 restricted stock units ("RSU") to the lender, ALT Debt II, LP wherein each RSU is exercisable into one (1) Class A Subordinate Voting Share upon the earliest of certain specified conditions at an issue price of C\$0.31 per RSU.

On November 8, 2023, the Company shuttered operations at the Ann Arbor, Michigan dispensary location. As of September 30, 2023, this event did not qualify for discontinued operations treatment. For the nine months ended September 30, 2023, the Michigan dispensary contributed \$1.2 million in revenue and a net loss of \$0.4 million.

On November 17, 2023, the Company entered into an agreement with a third party to purchase a significant piece of equipment for a purchase price of \$1.4 million. \$0.95 million of the purchase price is to be paid in cash with the remaining \$0.5 million contemplated in a promissory note. This equipment was classified as assets related to discontinued operations as of September 30, 2023.

On November 17, 2023, the Company entered into a Membership Interest Purchase Agreement to acquire 100% of the issued and outstanding equity interests in Westside Visionaries, LLC ("Westside") for a total purchase price of \$2.4 million to be paid in cash, a promissory note, and Class A Subordinate Voting Shares. In addition, Westside has issued a \$2 million secured promissory note to fund the permitted expansion for the dispensary build out with a maturity date of the earlier of the second anniversary of closing (license approval) or the third anniversary of the date on which the note was executed. Westside holds a conditional adult use dispensary license in the state of Illinois which shall convert to a state license upon regulatory approval. The transfer of the license is subject to regulatory approval.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Investors should read the following discussion in conjunction with the unaudited financial statements and notes thereto included under Part 1, Item 1 of this Quarterly Report on Form 10-Q. In addition, investors should refer to our audited consolidated financial statements and notes thereto and related Management's Discussion and Analysis of Financial Condition and Results of Operations appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

Disclosure Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking information about the Company that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "guidance," "expect," "will," "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "suggests," "potential" and similar expressions are intended to identify forward-looking statements. These statements include information regarding our plans, strategies, and expectations of future financial performance and prospects. Forward-looking statements are not guarantees of performance. These statements are based upon the current beliefs and expectations of our management and are subject to significant risk and uncertainties that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot assure investors that the expectations will prove to be correct. Among the factors that could cause actual results to differ materially from the expectations are acts of war or terrorism and the impact on the social and economic conditions in the United States, and changes in the legalization of marijuana across the United States. More information on factors that could cause actual results to differ materially from those anticipated is included from time to time in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2022. New risk factors emerge over time and it is not possible to predict all such risk factors, or to assess the impact such risk factors have on the business. We undertake no obligation to update publicly any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Overview

4Front Ventures Corp. ("4Front", the "Company", "we" or "our") has two primary operating segments: THC Cannabis and CBD Wellness. With regard to its THC Cannabis segment, the Company operates six dispensaries and four production and cultivation facilities in Massachusetts, Illinois, and Michigan as of September 30, 2023. The Company's six "MISSION" branded dispensaries are located in: Brookline, MA; Georgetown, MA; Worcester, MA; South Shore (Chicago), IL; Calumet City, IL; and Ann Arbor, MI. The Company's cultivation and production assets are detailed in our Annual Report on Form 10-K for the year ended December 31, 2022.

4Front operations are structured in key geographic locations across the United States to scale operations efficiently and position the company for future growth opportunities as cannabis legalization efforts continue across the U.S. and federally. Management intends to continue scaling operations in Illinois and Massachusetts to increase its market share. The Company has made significant investments in manufacturing facilities in each of these locations. In January 2022, the Company acquired a new cultivation facility in Holliston, MA in the New England Cannabis Corporation ("NECC") acquisition, which doubled the Company's cultivation footprint in the Massachusetts market. The Company has continued to expand its footprint in the Illinois market with the development of the Matteson facility which is currently in progress. Additionally, the company entered into an agreement to purchase a cannabis license to enable the Company to open an additional dispensary in the state of Illinois. In addition to scaling and driving operational effectiveness, the Company will also focus on developing trusted brand products to grow revenue, build customer loyalty and market share.

As part of its THC Cannabis segment, the Company also leases real estate and sells equipment, supplies, and intellectual property to cannabis producers in the state of Washington.

The Company's CBD Wellness segment is focused upon its ownership and operation of its wholly owned subsidiary, Pure Ratios Holdings, Inc. ("Pure Ratios"), a CBD-focused wellness company in California, that sells non-THC products throughout the United States.

While marijuana is legal under the laws of several U.S. states (with varying restrictions), the United States Federal Controlled Substances Act classifies all "marijuana" as a Schedule I drug, whether for medical or recreational use. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision.

Recent Developments

Discontinued THC Operations in California

During the fiscal quarter ended September 30, 2023, the Company ceased its THC cannabis cultivation and production operations in the state of California (together, the "California operations"). The Company concluded the abandonment of its California operations represented a strategic shift and thus all assets and liabilities to the operations within the state of California were classified as discontinued operations. Revenue and expenses, gains or losses relating to the discontinuation of California operations were eliminated from profit or loss from the Company's continuing operations and are shown as a single line item in the consolidated statements of operations for all periods presented.

Asset Acquisition of Euphoria, LLC

On March 27, 2023, the Company entered into a Membership Interest Purchase Agreement to acquire 100% of the issued and outstanding equity interests in Euphoria, LLC which holds a conditional adult use dispensary license in the state of Illinois. The transfer of the license is subject to regulatory approval. Please see Note 5 of the financial statements for a full description of the transaction.

Management Changes

Effective July 31, 2023, Keith Adams resigned as Chief Financial Officer of the Company. Effective August 4, 2023, Nicole Frederick was named Interim Chief Financial Officer.

Modification of Lease Agreement

On July 7, 2023, the Company amended its lease agreement for the cultivation and production facility in Matteson, Illinois to apply a portion of the security deposit to pay one-half of the monthly base rent for the four month period through November 30, 2023; to defer payment of the \$2.2 million increase in security deposit to be funded as draws on the tenant improvement allowance through November 30, 2023; and to make pro rata payments of such deferred payments equal to 1/12 of the aggregate amount, concurrently with monthly base rent installments, for the twelve month period commencing January 1, 2024.

Amendment of Senior Secured Debt

In July 2023, the Company entered into a definitive agreement with the Company's senior secured lender, LI Lending, LLC ("Lender") to extend the maturity date, reduce the interest payable, and expand the third-party financings allowed under the December 17, 2020 Amended and Restated Loan and Security Agreement ("Loan") between 4Front and Lender on terms and conditions set out in the Term Sheet.

The Lender will extend the maturity date of the Loan to May 1, 2026, reduce the interest payable to 12.0% per year, payable monthly, and allow for in excess of \$30.0 million additional senior secured financing.

The Company shall pay an extension fee of \$0.52 million payable in cash on May 1, 2024. In addition, the Company shall issue warrants equal to 33% of the loan balance, or approximately \$17.06 million, wherein each warrant shall be exercisable into one Subordinate Voting Share of the Company at an exercise price not less than \$0.17 through May 1, 2026. Refer to Note 8 of the financial statements for further information.

Debt Amendments

On September 28, 2023, the Company amended the unsecured promissory note dated September 20, 2019 wherein the interest rate was reduced to 11% per annum through March 15, 2024 and the maturity date was extended to November 30, 2024. By March 15, 2024, the parties will agree to an interest rate on the promissory note through maturity. The Company shall make monthly payments of \$25,000 through December 2023 and monthly interest payments thereafter.

On October 2, 2023, the Company amended the unsecured convertible promissory note with Healthy Pharms Inc. wherein the interest rate was amended to 12.0% per annum and the maturity date was extended to December 18, 2024. Beginning January 15, 2024, the Company shall make monthly cash payments of \$50,000 through the maturity date. In November 2023, the Company issued 10,359,372 Class A Subordinate Voting Shares to the noteholder at an exercise price of C\$0.26 per share to settle \$1,992,187 of the promissory note.

On October 6, 2023, the Company amended the October 2021 Convertible Note wherein payment of interest shall be deferred and become due and payable upon the earlier of the maturity date, a change of control, or event of default under the existing agreement terms. In addition, the outstanding balance, including any deferred interest payments, shall accrue interest at a rate of 10.0% per annum through maturity. The conversion price was amended to \$0.23 per share.

On October 10, 2023, the Company amended the Promissory Note Purchase Agreement with HI 4Front, LLC and Navy Capital Green Fund, LP wherein the maturity date was extended to January 1, 2024. As consideration for the amendment, the Company paid an extension fee of C\$65,000 in the form of 1,283,425 share purchase warrants, wherein each warrant is exercisable into one (1) Subordinate Voting Share at an exercise price of US\$0.20 and expire on October 17, 2027.

\$10M Senior Secured Credit Facility

On October 13, 2023, the Company entered into a senior secured credit facility for an aggregate principal up to \$10,000,000 in which a term loan in the amount of \$6,000,000 was drawn on the closing date and a second tranche of \$4,000,000 is available to be drawn through July 13, 2023. The term loans accrue interest paid monthly in arrears at a rate equal to the greater of (a) the sum of the prime rate and 7.0% and (b) 15.5% per annum. The term loans mature on December 1, 2023 and include extension terms under certain circumstances no further than September 30, 2026. For each term loan, the Company shall pay an origination fee equal to 7.0% of the principal amount of the term loan upon issuance. In addition, the Company shall pay a commitment fee on the undrawn second tranche which shall accrue at a rate per annum of 2.0% through the earlier of July 13, 2023 and the date on which the maximum facility amount is drawn. The Company may prepay the term loans, in whole or in part, at any time subject to the prepayment fee based on the date of the prepayment. Further, the Company shall pay an exit fee of \$1,400,000 upon the earlier of the maturity date or the date on which the obligations are paid in full. The funds are committed to building out the Company's retail operations in Illinois in connection with the imminent launch of its new state-of-the-art cultivation and processing facility in Matteson. Refer to Note 19 of the financial statements for further information.

Closure of Michigan Location

On November 8, 2023, the Company shuttered operations at the Ann Arbor, Michigan dispensary location. As of September 30, 2023, this event did not qualify for discontinued operations treatment. For the nine months ended September 30, 2023, the Michigan dispensary contributed \$1.2 million in revenue and a net loss of \$0.4 million.

Equipment Sale

On November 17, 2023, the Company entered into an agreement with a third party to purchase a significant piece of equipment for a purchase price of \$1.4 million. \$0.95 million of the purchase price is to be paid in cash with the remaining \$0.5 million contemplated in a promissory note. This equipment was classified as assets related to discontinued operations as of September 30, 2023.

Asset Acquisition of Westside Visionaries, LLC

On November 17, 2023, the Company entered into a Membership Interest Purchase Agreement to acquire 100% of the issued and outstanding equity interests in Westside Visionaries, LLC ("Westside") for a total purchase price of \$2.4 million to be paid in cash, a promissory note, and Class A Subordinate Voting Shares. In addition, Westside has issued a \$2 million secured promissory note to fund the permitted expansion for the dispensary build out with a maturity date of the earlier of the second anniversary of closing (license approval) or the third anniversary of the date on which the note was executed. Westside holds a conditional adult use dispensary license in the state of Illinois which shall convert to a state license upon regulatory approval. The transfer of the license is subject to regulatory approval.

Critical Accounting Policies and use of Estimates

Our management's discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). Critical accounting policies and estimates are identified and discussed in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 30, 2023. Although we believe our estimates and judgments are reasonable, they are based upon information available at the time the judgment or estimate is made. Actual results may differ significantly from estimates under different assumptions or conditions.

Results of Operations

Three Months Ended September 30, 2023 Compared With Three Months Ended September 30, 2022

The following table sets forth our results of operations for the three months ended September 30, 2023 and 2022:

	For the Three Months Ended September 30,		Change	
	2023	2022	\$	%
Revenue from Sale of Goods	\$ 20,110	\$ 25,035	\$ (4,925)	20 %
Real Estate Income	2,892	3,065	(173)	6 %
Total Revenues	23,002	28,100	(5,098)	18 %
Cost of Goods Sold	(13,722)	(11,039)	(2,683)	24 %
Gross Profit	9,280	17,061	(7,781)	46 %
Total Operating Expense	23,419	14,720	8,699	59 %
Income (Loss) from Continuing Operations	(14,139)	2,341	(16,480)	704 %
Total Other Expense, net	(16,488)	(3,010)	(13,478)	448 %
Net Loss from Continuing Operations Before Income Taxes	(30,627)	(669)	(29,958)	4477 %
Income Tax Benefit (Expense)	4,199	(3,321)	7,520	226 %
Net Loss from Continuing Operations	\$ (26,428)	\$ (3,990)	\$ (22,438)	562 %
Net Loss from Discontinued Operations, Net of Taxes	(35,668)	(4,611)	(31,057)	674 %
Net Loss	\$ (62,096)	\$ (8,601)	\$ (53,495)	622 %

Revenue from Sale of Goods

Revenue from the sale of goods related to continuing operations for the three months ended September 30, 2023 was \$20.1 million, a decrease of \$4.9 million or 20% compared to the three months ended September 30, 2022. Refer to the segment discussion below for specific revenue drivers quarter over quarter.

Real Estate Income

Real estate income from leasing cannabis production facilities for the three months ended September 30, 2023 was \$2.9 million, which remained materially consistent compared to the \$3.1 million recognized for the three months ended September 30, 2022.

Total revenue from continuing operations in the reportable segments from which we operate were as follows:

	For the Three Months Ended September 30,		Change	
	2023	2022	\$	%
THC Cannabis	\$ 22,840	\$ 28,276	\$ (5,436)	19%
CBD Wellness	162	(176)	338	192%
Total Net Revenues	\$ 23,002	\$ 28,100	\$ (5,098)	18%

Net revenues for the THC cannabis segment were \$22.8 million for the three months ended September 30, 2023, a decrease of \$5.4 million or 19%, compared to the three months ended September 30, 2022. The decrease was primarily attributable to price compression in Illinois as well as liquidation of products and pricing declines year-over-year in Massachusetts.

Net revenues for the CBD wellness segment were materially consistent for the three months ended September 30, 2023 and 2022.

Cost of Goods Sold

Cost of goods sold for the three months ended September 30, 2023 was \$13.7 million, an increase of \$2.7 million or 24% compared to \$11.0 million for the three months ended September 30, 2022. Due to the economic environment as well as cannabis market and regulations compared to the prior year, the Company has experienced an increase in the direct cost of labor and materials, indirect costs such as utilities and supplies used in the growing process, and indirect labor costs for individuals involved in the growing, quality control and inventory processes, as well as certain facility costs.

Gross Profit

Gross profit for the three months ended September 30, 2023 was \$9.3 million, or 40% of revenue, compared to \$17.1 million, or 61% of revenue, for the three months ended September 30, 2022. The decrease in gross profit percentage of 20% was primarily due to increase in cost of goods sold as described above coupled with a general decline in the cannabis market compared to the prior year.

Total Operating Expenses

Operating expenses consist of selling, general and administrative expenses, depreciation and amortization, equity based compensation expense, and transaction related expenses. Total operating expenses for the three months ended September 30, 2023 were \$23.4 million, an increase of \$8.7 million or 59%, as compared to the three months ended September 30, 2022. The increase was primarily attributed to a one time reserve for bad debt on our Washington sublease revenue of \$6.5 million recorded in Q3 2023 as compared to nil in Q3 2022 and the issuance of RSUs and stock options as part of the Company's compensation structure during the current quarter.

Total Other Expense, net

Other expense consists primarily of interest expense, change in fair value of derivative liability, and other expenses. Total other expense for the three months ended September 30, 2023 was \$16.5 million, as compared to \$3.0 million for the three months ended September 30, 2022. The increase of \$13.5 million was primarily due to a change in fair value of derivative liability of \$11.9 million recognized during the current period for the warrants issued in August 2023.

Net Loss

Net loss from continuing operations for the three months ended September 30, 2023 was \$26.4 million, compared to \$4.0 million for the three months ended September 30, 2022. The increase in net loss for the three months ended September 30, 2023 was primarily attributable to the changes in fair value of derivative liability, the increase in operating expenses, and the decline in gross profit as described above.

Nine Months Ended September 30, 2023 Compared With Nine Months Ended September 30, 2022

The following table sets forth our results of operations for the nine months ended September 30, 2023 and 2022:

	For the Nine Months Ended September 30,		Change	
	2023	2022	\$	%
Revenue from Sale of Goods	\$ 67,709	\$ 70,847	\$ (3,138)	4 %
Real Estate Income	8,747	8,981	(234)	3 %
Total Revenues	76,456	79,828	(3,372)	4 %
Cost of Goods Sold	(38,884)	(35,680)	(3,204)	9 %
Gross Profit	37,572	44,148	(6,576)	15 %
Total Operating Expense	52,041	40,870	11,171	27 %
Income (Loss) from Continuing Operations	(14,469)	3,278	(17,747)	541 %
Total Other Expense, net	(24,276)	(3,069)	(21,207)	691 %
Net Income (Loss) from Continuing Operations Before Income Taxes	(38,745)	209	(38,954)	18646 %
Income Tax Expense	(818)	(9,801)	8,983	92 %
Net Loss from Continuing Operations	\$ (39,563)	\$ (9,592)	\$ (29,971)	312 %
Net Loss from Discontinued Operations, Net of Taxes	(45,389)	(11,449)	(33,940)	296 %
Net Loss	\$ (84,952)	\$ (21,041)	\$ (63,911)	304 %

Revenue from Sale of Goods

Revenue from sale of goods related to continuing operations for the nine months ended September 30, 2023 was \$67.7 million, a decrease of \$3.1 million or 4% compared to the nine months ended September 30, 2022. Refer to the segment discussion below for specific revenue drivers quarter over quarter.

Real Estate Income

Real estate income from leasing cannabis production facilities for the nine months ended September 30, 2023 was \$8.7 million, which remained materially consistent compared to the \$9.0 million recognized for the nine months ended September 30, 2022.

Total revenue from continuing operations in the reportable segments from which we operate were as follows:

	For the Nine Months Ended September 30,		Change	
	2023	2022	\$	%
THC Cannabis	\$ 75,815	\$ 79,495	\$ (3,680)	5%
CBD Wellness	641	333	308	92%
Total Net Revenues	\$ 76,456	\$ 79,828	\$ (3,372)	4%

Net revenues for the THC cannabis segment were \$75.8 million for the nine months ended September 30, 2023, a decrease of \$3.7 million or 5%, compared to the nine months ended September 30, 2022. The decrease was primarily attributed to price compression in Illinois as well as liquidation of products and pricing declines year-over-year in Massachusetts. Net revenues for the CBD wellness segment were materially consistent for the nine months ended September 30, 2023 and 2022.

Cost of Goods Sold

Cost of goods sold for the nine months ended September 30, 2023 was \$38.9 million, an increase of \$3.2 million or 9% compared to \$35.7 million for the nine months ended September 30, 2022. Due to the economic environment as well as cannabis market and regulations during 2023, the Company has experienced an increase in the direct cost of labor and materials, indirect costs such as utilities and supplies used in the growing process, and indirect labor costs for individuals involved in the growing, quality control and inventory processes, as well as certain facility costs.

Gross Profit

Gross profit for the nine months ended September 30, 2023 was \$37.6 million, or 49% of revenue, compared to \$44.1 million, or 55% of revenue, for the nine months ended September 30, 2022. The decrease in gross profit percentage of 6% was primarily due to the increase in cost of goods sold as described above coupled with pricing compression across the Company's markets.

Total Operating Expenses

Operating expenses consist of selling, general and administrative expenses, depreciation and amortization, equity based compensation expense, and transaction related expenses. Total operating expenses for the nine months ended September 30, 2023 was \$52.0 million, an increase of \$11.2 million or 27%, as compared to the nine months ended September 30, 2022. This increase was attributed to an additional \$3.2 million in lease related expenses resulting from expansion of the Company's operations, an increase in bad debt expense of \$6.5 million, and an increase in share based compensation primarily due to the issuance of 9,300,250 shares of Subordinate Voting Shares to the Company's Chief Executive Officer, Leo Gontmakher, and the issuances of restricted share options for certain executives during the fiscal third quarter of 2023 as compared to the same period in 2022.

Total Other Expense, net

Other expense consists primarily of interest expense, change in fair value of derivative liability, gain on contingent consideration payable, and other expenses. Total other expense for the nine months ended September 30, 2023 was \$24.3 million, as compared to \$3.1 million for the nine months ended September 30, 2022. The increase of \$21.2 million was primarily due to a loss on changes in fair value of derivative liability of \$11.9 million in the current year as compared to a gain on changes in fair value of derivative liability of \$3.5 million in the prior year. In addition, the Company recognized a gain on contingent consideration payable of \$2.4 million for the nine months ended September 30, 2022 versus none in the current year. During the nine months ended September 30, 2023, other expense of \$2.6 million primarily consisted of an expense accrual of \$1.3 million related to an Illinois cultivation tax audit while no such transactions occurred in the prior year.

Net Loss

Net loss from continuing operations for the nine months ended September 30, 2023 was \$39.6 million, compared to \$9.6 million for the nine months ended September 30, 2022. The increase in net loss for the nine months ended September 30, 2023 was primarily attributable to the changes in fair value of derivative liability, the increase in general and administrative expenses, and the decline in gross profit as described above.

Non-GAAP Financial and Performance Measures

In addition to providing financial measurements based on GAAP, we provide additional financial metrics that are not prepared in accordance with GAAP. Management uses non-GAAP financial measures, in addition to GAAP financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes and to evaluate the Company's financial performance. Management uses the non-GAAP measurement of adjusted EBITDA, which we believe reflects our ongoing business in a manner that allows for meaningful comparisons and analysis of trends in the business, as it facilitates comparing financial results across accounting periods. We also believe this non-GAAP financial measure enables investors to evaluate the Company's operating results and future prospects in the same manner as management. This non-GAAP financial measures may also exclude expenses and gains that may be unusual in nature, infrequent or not reflective of the Company's ongoing operating results. As there are no standardized methods of calculating non-GAAP measures, our methods may differ from those used by others, and accordingly, the use of these measures may not be directly comparable to similarly titled measures used by others. Accordingly, non-GAAP measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP.

Adjusted EBITDA

Adjusted EBITDA is a financial measure that is not calculated in accordance with U.S. GAAP. Management believes because Adjusted EBITDA excludes (a) certain non-cash expenses (such as depreciation, amortization and stock-based compensation) and (b) expenses that are not reflective of the Company's core operating results over time (such as restructuring costs, litigation or dispute settlement charges or gains, and transaction-related costs), it represents a clearer picture of what the Company's operations could be doing. Adjusted EBITDA is defined by the Company as detailed below. This measure provides investors with additional useful information to measure the Company's financial performance, particularly with respect to changes in performance from period to period. The Company's management uses Adjusted EBITDA (a) as a measure of operating performance, (b) for planning and forecasting in future periods, and (c) in communications with the Company's board of directors concerning the Company's financial performance.

The Company's presentation of Adjusted EBITDA are not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation and should not be used by investors as a substitute or alternative to net income or any measure of financial performance calculated and presented in accordance with U.S. GAAP. Instead, management believes Adjusted EBITDA should be used to supplement the Company's financial measures derived in accordance with U.S. GAAP to provide a more complete understanding of the trends affecting the business.

Although Adjusted EBITDA is frequently used by investors and securities analysts in their evaluations of companies, Adjusted EBITDA has limitations as an analytical tool, and investors should not consider it in isolation or as a substitute for, or more meaningful than, amounts determined in accordance with U.S. GAAP. Some of the limitations to using non-GAAP measures as an analytical tool are (a) they do not reflect the Company's interest income and expense, or the requirements necessary to service interest or principal payments on the Company's debt, (b) they do not reflect future requirements for capital expenditures or contractual commitments, and (c) although depreciation and amortization charges are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and non-GAAP measures do not reflect any cash requirements for such replacements. For comparative purposes, certain prior year amounts have been reclassified to conform to the current year presentation.

The following table reconciles Net Loss to Adjusted EBITDA for the three and nine months ended September 30, 2023 and 2022:

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2023	2022	2023	2022
Net loss (GAAP)	\$ (62,096)	\$ (8,601)	\$ (84,952)	\$ (21,041)
Less: Net loss from discontinued operations, net of taxes	35,668	4,611	45,389	11,449
Net loss from continuing operations	(26,428)	(3,990)	(39,563)	(9,592)
Interest income	21	(6)	—	(8)
Interest expense	3,322	3,642	9,561	9,066
Income tax expense	(4,199)	3,321	818	9,801
Depreciation and amortization	1,416	1,564	4,222	4,594
EBITDA from Continuing Operations (Non-GAAP)	\$ (25,868)	\$ 4,531	\$ (24,962)	\$ 13,861
Share-based compensation	3,678	863	4,912	2,291
Impairment of goodwill and intangible assets	—	—	—	—
Change in fair value of derivative liability	11,931	(420)	11,931	(3,494)
Change in fair value of contingent consideration	—	—	—	(2,393)
Loss on disposal and lease termination	160	—	160	—
Loss on litigation settlement	—	250	3	250
Sale leaseback related interest expense and non-cash operating lease amortization	1,418	1,072	4,309	3,901
Facility start-up costs/under-absorbed overhead costs	2,987	1,882	8,907	5,736
Fair value mark-up for acquired inventory	—	—	—	—
Acquisition, transaction, and other non-cash costs	9,154	—	10,459	3,840
Adjusted EBITDA from Continuing Operations (Non-GAAP)	\$ 3,460	\$ 8,178	\$ 15,719	\$ 23,992

Adjusted EBITDA should not be considered in isolation from, or as a substitute for, Net Loss. There are a number of limitations related to the use of Adjusted EBITDA as compared to Net Loss, the closest comparable GAAP measure. Adjusted EBITDA, as defined by the Company, excludes from Net Loss:

- Interest income and expense;
- Current income tax expense;
- Non-cash depreciation and amortization expense;
- Non-cash share-based compensation expense;
- Non-cash changes in fair value of derivative liability and contingent consideration;
- Loss recognized on litigation settlements;
- Sale leaseback related interest expense and non-cash operating lease amortization;
- Facility start-up costs and under-absorbed overhead costs; and
- Acquisition, transaction, and other non-cash costs, which vary significantly by transactions and are excluded to evaluate ongoing operating results.

Liquidity and Capital Resources

As of September 30, 2023 and December 31, 2022, we had total current liabilities of \$97.9 million and \$77.5 million, respectively, and current assets of \$33.8 million and \$53.3 million, respectively, to meet our current obligations. As of September 30, 2023 and December 31, 2022, we had a working capital deficit of \$64.2 million compared to \$24.2 million. The decline in working capital of \$40.0 million was primarily driven by a decrease in cash of \$11.5 million as the Company continues its retail expansion strategy and completes the buildout of the cultivation and production facility in Matteson. This was coupled with an increase in taxes payable of \$2.0 million given the Company's expanded operations compared to the prior year in addition to a derivative liability of \$16.1 million as of September 30, 2023 related to warrants issued in July 2023 in connection with the amendment of the senior secured debt with LI Lending. The conditions described above raise substantial doubt with respect to the Company's ability to meet its obligations for at least one year from the issuance of these consolidated financial statements, and therefore, to continue as a going concern.

The Company is an early-stage growth company. It is generating cash from sales and is deploying its capital reserves to acquire and develop assets capable of producing additional revenues and earnings over both the immediate and near term. Capital reserves are being utilized for capital expenditures and improvements in existing facilities, product development and marketing, as well as customer, supplier and investor and industry relations. Historically, the Company has raised capital as needed however there is no guarantee the Company will be able to continue to raise funds in the same manner it has historically.

Cash Flows

Cash Flows from discontinued operations are separately presented on the statement of cash flow for each operating, investing, and financing section of the statement. For liquidity purposes, the focus of this section is on the cash flow from continuing operations which is expected to affect future liquidity and capital resources.

Net Cash Provided by Continuing Operating Activities

Net cash provided by continuing operating activities was \$3.4 million for the nine months ended September 30, 2023, an decrease of \$6.2 million as compared to \$9.5 million for the nine months ended September 30, 2022. The increase was primarily attributable to the increase in net loss as a result of a decrease in gross profits as described above.

Net Cash Used in Continuing Investing Activities

Net cash used in continuing investing activities was \$0.5 million for the nine months ended September 30, 2023, a decrease of \$26.1 million as compared to \$26.6 million for the nine months ended September 30, 2022. The decrease was primarily attributable to the financing of acquisition activity in 2022. In the nine months ended September 30, 2023, there were no comparable transactions.

Net Cash (Used in) Provided by Continuing Financing Activities

Net cash used in financing activities for continuing operations was \$6.6 million for nine months ended September 30, 2023, a decrease of \$18.3 million as compared to \$11.7 million of cash provided by financing activities for the nine months ended September 30, 2022. The decrease was primarily attributable to the non-recurring nature of the proceeds from the construction finance liability of \$16.0 million associated with the NECC acquisition during the nine months ended September 30, 2022.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Critical Accounting Policies

We review new accounting standards as issued. Although some of these accounting standards issued or effective after the end of our previous fiscal year may be applicable to the Company, we have not identified any standards that we believe merit further discussion. We do not expect the adoption of any recently issued accounting pronouncements to have a significant impact on our financial position, results of operations, or cash flows.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15 under the Exchange Act, our management has carried out an evaluation, with the participation and under the supervision of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2023. Disclosure controls and procedures refer to controls and other procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating and implementing possible controls and procedures.

Inherent Limitations on Effectiveness of Controls

Management recognizes that a control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or error, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Changes in Internal Control over Financial Reporting

There have been no changes in the Company's internal control over financial reporting during the nine months ended September 30, 2023 that have materially affected, or that are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

On January 26, 2022, Savills, Inc. sued the Company in the U.S. District Court for the Southern District of New York. That lawsuit alleged the Company had breached an alleged agreement with Savills under which the Company was allegedly required to pay Savills a percentage of savings realized under certain incentive programs offered in some jurisdictions, which Savills would assist the Company in obtaining. Savills claimed damages of approximately \$19.4 million in connection with its claim that it obtained benefits for the Company allegedly valued at over \$129.0 million. The Company denied these allegations, denied the Company had obtained such benefits, disputed Savills' characterization of the facts, and denied liability. The Company filed a counterclaim against Savills alleging breach of contract by Savills. On August 3, 2022, the parties reached a confidential settlement in principle and agreed to dismissal of all claims, which was finalized on September 12, 2022 and required the Company to pay \$0.25 million in five monthly installments beginning in October 2022. In addition to this initial payment, there is a portion of the settlement that is contingent on future tax savings. As of September 30, 2023, this additional contingent amount is not reasonably estimable.

On May 9, 2023, Florival LLC ("Florival") sued the Company in the California Superior Court for the County of Santa Cruz. The lawsuit alleged the Company had breached an agreement with Florival under which Company subsidiary Island Global Holdings, Inc. ("Island") agreed to purchase the membership interests of licensed cannabis cultivator Gold Coast Gardens, LLC. Florival claimed damages of \$0.85 million. The Company denied it had any direct liability under the agreement, which was executed two years before the Company's acquisition of Island and asserted an unclean hands defense on behalf of both the Company and Island based on Florival's inequitable conduct during the litigation. On November 7, 2023, the court entered summary judgment against the Company and Island. The Company and Island intends to appeal the decision. Management has accrued \$0.85 million related to this matter as of September 30, 2023.

On September 14, 2023, Teichman Enterprises, Inc. ("Teichman") sued Company subsidiary 4Front California Capital Holdings, Inc. ("4Front CA") in the California Superior Court for the County of Los Angeles. The lawsuit alleged 4Front CA had breached a lease with Teichman for 4Front CA's facility in Commerce, California by failing to pay rent due under the lease. Teichman sought possession of the property and damages of \$0.6 million. 4Front CA denied the allegations, but vacated the facility. Trial is set for January 2024. Management has accrued \$0.6 million related to this matter as of September 30, 2023.

On September 29, 2023, Teichman Enterprises, Inc. sued 4Front CA and the Company in the Superior Court for the County of Los Angeles. The lawsuit alleged the Company had breached a lease agreement with Teichman under which the Company entered into a 10 year lease commitment ending on January 31, 2029, and that the Company breached its guarantee of the lease. Teichman has alleged total rent owed under the lease agreement is \$13.4 million in addition to a license fee of \$1.0 million. Total damages sought from Teichman under the lease contracts is \$15.5 million. 4Front CA and the Company denied the allegations in the complaint, and denied that Teichman was entitled to the full amount of damages claimed due to Teichman's obligation to mitigate. Based on management's review of case, the Company has accrued \$2.0 million associated with this legal liability as of September 30, 2023.

Apart from the foregoing and ongoing legal proceedings, from time to time, we may be subject to various other legal proceedings and claims that are routine and incidental to our business. Although some of the legal proceedings set forth herein may result in adverse decisions or settlements, management believes that the final disposition of such matters will not have a material adverse effect on our business, financial position, results of operations or cash flows.

Item 1A. Risk Factors

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit Number	Exhibit Description	Form	Filing Date	Exhibit Number	Filed Herewith
31.1	Certification of the Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act				x
31.2	Certification of the Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act				x
32.1	Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Rule 13a-14(b) Under the Securities Exchange Act of 1934 and Section 1350 of Chapter 60 of Title 18 of the United States Code *				x
101.INS	XBRL Instance Document				
101.SCH	XBRL Taxonomy Extension Schema Document				
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document				
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document				
101.LAB	XBRL Taxonomy Extension Label Linkbase Document				
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document				
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)				

+ Indicates management contract or compensatory plan.

* This certification is being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, and it is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

4FRONT VENTURES CORP.

Date: November 20, 2023

By: /s/ Leonid Gontmakher

Leonid Gontmakher

Chief Executive Officer and Director
(Principal Executive Officer)

Date: November 20, 2023

By: /s/ Nicole Frederick

Nicole Frederick

Interim Chief Financial Officer
(Principal Financial Officer)

**Certification of Chief Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, Leonid Gontmakher, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of 4Front Ventures Corp.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 20, 2023

/s/ Leonid Gontmakher

Leonid Gontmakher, Chief Executive Officer
(principal executive officer)

**Certification of Interim Chief Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, Nicole Frederick, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of 4Front Ventures Corp.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 20, 2023

/s/ Nicole Frederick

Nicole Frederick, Interim Chief Financial Officer
(principal financial and accounting officer)

Certifications of Chief Executive Officer and Interim Chief Financial Officer

**Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002**

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Leonid Gontmakher, Chief Executive Officer (principal executive officer) of 4Front Ventures Corp. (the “Company”), and Nicole Frederick, Interim Chief Financial Officer (principal financial and accounting officer) of the Company, each hereby certifies that, to the best of his knowledge:

- 1) The Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, to which this certification is attached as Exhibit 32.1 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- 2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 20, 2023

/s/ Leonid Gontmakher

Leonid Gontmakher
Chief Executive Officer
(*principal executive officer*)

/s/ Nicole Frederick

Nicole Frederick
Interim Chief Financial Officer
(*principal financial and accounting officer*)

The foregoing certifications are being furnished pursuant to 18 U.S.C. Section 1350. They are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the Company, regardless of any general incorporation language in such filing.